Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles

被引:106
作者
Peleg-Shulman, T [1 ]
Najajreh, Y [1 ]
Gibson, D [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel
关键词
cisplatin; transplatin; protein binding; electrospray ionization mass spectrometry (ESI-MS);
D O I
10.1016/S0162-0134(02)00362-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this manuscript we report on the interactions of cis-DDP (cisplatin, cis-diamminedichloroplatinum(II)) and trans-DDP (transplatin, trans-diamminedichloroplatinum(II)) with two model proteins, ubiquitin (Ub) and horse heart myoglobin (Mb), and attempt to answer the question whether proteins that have methionine-Pt adducts can transfer the platinum to biological nucleophiles and particularly to DNA. Our study shows that cisplatin and transplatin form different adducts with ubiquitin: transplatin forms one major adduct, trans[Pt(Ub)(NH3)(2)Cl], while cisplatin forms four distinct adducts, [Pt(Ub)(NH3)(2)Cl], [Pt(Ub)(NH3)(2)(H2O)], [Pt(Ub)(NH3)(2)], and [Pt(Ub)(NH3)]. When binding ubiquitin, Metl is the preferred binding site of cisplatin, but not of transplatin. Cisplatin binds faster than transplatin to both ubiquitin and horse heart myoglobin. Both cisplatin and transplatin adducts form stable ternary adducts when reacted with 5'-guanosine monophosphate (5'-GMP) or a tetranucleotide. No transfer of the Pt moiety from the proteins to the nucleotides was observed. Glutathione efficiently removes the platinum from preformed adducts of both cisplatin and transplatin with ubiquitin. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 27 条
[21]   Cisplatin-protein adducts are efficiently removed by glutathione but not by 5′-guanosine monophosphate [J].
Peleg-Shulman, T ;
Gibson, D .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (13) :3171-3172
[22]   Current status of the development of trans-platinum antitumor drugs [J].
Pérez, JM ;
Fuertes, MA ;
Alonso, C ;
Navarro-Ranninger, C .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (02) :109-120
[23]   Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? [J].
Reedijk, J .
CHEMICAL REVIEWS, 1999, 99 (09) :2499-2510
[24]   CRYSTAL-STRUCTURE OF DOUBLE-STRANDED DNA CONTAINING THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN [J].
TAKAHARA, PM ;
ROSENZWEIG, AC ;
FREDERICK, CA ;
LIPPARD, SJ .
NATURE, 1995, 377 (6550) :649-652
[25]   Reaction of DNA oligonucleotides with [Pt(dien)GSMe]2+ (GSMe = S-methylated glutathione) and cis-[Pt(NH3)2(GSMe)2]2+:: evidence of oligonucleotide platination via sulfur-coordinated platinum intermediates [J].
Teuben, JM ;
Reedijk, J .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2000, 5 (04) :463-468
[26]   STRUCTURE OF UBIQUITIN REFINED AT 1.8 A RESOLUTION [J].
VIJAYKUMAR, S ;
BUGG, CE ;
COOK, WJ .
JOURNAL OF MOLECULAR BIOLOGY, 1987, 194 (03) :531-544
[27]  
WOLTERS D, 1999, J CHEM SOC DA, V7, P112